ScrutarSign up free

Cencora, Inc. (COR)

SEC filings, insider trading & institutional ownership from EDGAR.

NYSEHealth CareHealth Care Providers & Services

AmerisourceBergen Corporation is one of the largest global pharmaceutical sourcing and distribution services companies, serving healthcare providers and pharmaceutical/biotech manufacturers by improving patient access to products and enhancing patient care through an efficient pharmaceutical supply chain in both human and animal health. The company distributes brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter products, and home healthcare supplies to acute care hospitals, retail and mail order pharmacies, long-term care facilities, physician practices, veterinarians, and other providers across the United States and select global markets, while also offering value-added services such as data analytics, reimbursement consulting, logistics, inventory management, pharmacy automation, and packaging solutions. Operations are organized into two reportable segments: U.S. Healthcare Solutions, which includes pharmaceutical distribution, animal health (MWI Animal Health), consulting (Xcenda, Lash Group), and third-party logistics (ICS 3PL); and International Healthcare Solutions, comprising Alliance Healthcare, World Courier, Innomar, and Profarma, focused on pharmaceutical wholesale, specialty logistics, and commercialization services primarily in Europe and Canada.

The company's strategy centers on optimizing and growing both segments through operational efficiency, technology investment, and acquisitions—most notably the pending €1.28 billion acquisition of PharmaLex Holding GmbH, a life sciences services provider, expected to close by March 2023—as well as periodic divestitures of non-core businesses. Key industry growth drivers include an aging U.S. population, new pharmaceutical and biotech innovations, increased use of generics and biosimilars, expanded drug therapy utilization, and ongoing healthcare legislative developments, while the COVID-19 pandemic continues to present operational and financial uncertainties. The company's two largest customers, Walgreens Boots Alliance and Express Scripts, accounted for approximately 27% and 13% of fiscal 2022 revenue respectively, with its top 10 customers representing about 66% of total revenue; its ten largest suppliers accounted for approximately 46% of purchases.

AmerisourceBergen faces significant competition from McKesson Corporation, Cardinal Health, UPS Logistics, and other distributors, manufacturers, and specialty service providers. As of September 30, 2022, the company employed approximately 44,000 people, about 39,000 full-time, with roughly 39% based in the U.S. and 28% covered by collective bargaining agreements; it emphasizes diversity, equity, and inclusion initiatives, employee development, and comprehensive benefits programs. The company operates under extensive regulatory oversight from agencies including the DEA, FDA, and other U.S., U.K., and EU authorities, and must comply with laws such as the anti-kickback statute, False Claims Act, and the Drug Supply Chain Security Act, which governs traceability and licensing requirements for pharmaceutical wholesalers and logistics providers.

AI-summarized from Item 1 (Business) of the company's most recent 10-K filing.

RevenueFY2025
$321.33B
▲ 9.3%YoY
Net incomeFY2025
$1.55B
▲ 3.0%YoY
Diluted EPSFY2025
$7.96
▲ 5.7%YoY
Gross margin
3.6%
▲ 20 bpsYoY

Financials

As reported to the SEC via XBRL, no adjustments

All financials →
Revenue & net income
$100B$200B$300B$400B
FY2022FY2023FY2024FY2025
RevenueNet income
FY2025 highlightsfrom 10-K
Gross profit$11.48B
Operating income$2.63B
Diluted EPS$7.96
Gross margin3.6%
Net margin0.5%

Latest filings

10-K, 10-Q, 8-K, Form 4 & 13D/G. Sourced directly from SEC EDGAR

All filings →
FormFiledAccession
4SANCHEZ ROBERT EOct 6, 2026EDGAR
4Krikorian LazarusOct 5, 2026EDGAR
8-KSep 25, 2026EDGAR
4GREENBERG LON RSep 17, 2026EDGAR
4Krikorian LazarusSep 2, 2026EDGAR
4Campbell Elizabeth SAug 25, 2026EDGAR
8-KAug 14, 2026EDGAR
8-KAug 12, 2026EDGAR

COR's filings are public. The insight is one click away.

Scrutar's AI reads every COR filing and points out what matters. Red flags, risk shifts, disclosure quality and key relationships. Cited to the source, free with an account.

Analyze COR filingsNo credit cardAI reports included on the free plan

Never miss a COR filing.

Get an email when COR files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.

Free foreverNo account requiredOne-click unsubscribe

Protected by reCAPTCHA. Privacy & Terms

Data as of Oct 16, 2026Source: SEC EDGAR.